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Abstract: The implementation of strategies to mitigate possible cases of COVID-19 were addressed 
at the University of Alicante for the safe reopening of the 2020/2021 academic year. To discover the 
prevalence of immunity against SARS-CoV-2, a study was designed using a rapid immunoassay 
test (carried out between 6 and 22 July 2020), and in addition a cross-sectional survey was conducted 
on risk factors, symptoms, predisposition for becoming vaccinated, and sources of information 
about COVID-19. A random sample, stratified by students, faculty, and administrative staff, was 
selected. The seroprevalence found was 2.64% (39/1479; 95% CI 1.8–3.4), and the adjusted seroprev-
alence was 2.89% (95% CI 2.1–3.7). The average age of the students was 23.2 years old, and 47.6 years 
old for staff. In relation to COVID-19, the following was found: 17.7% pauci-symptomatic, 1.3% 
symptomatic, 5.5% contact with cases, 4.9% confined, and 0.3% PCR positive. More than 90% com-
plied with preventive measures. The proportion willing to receive the COVID-19 vaccine was 91%. 
Their sources of information were the Internet (74%) and television (70.1%). They requested that the 
university offer information (45.1%), training (27%), and provide Personal Protective Equipment 
(PPE) (26.3%). Lastly, 87.9% would repeat the test. A plan was established that included the follow-
up of cases and contacts, random sample testing, training courses, bimodal teaching, a specific web-
site, and the distribution of PPE. 
Keywords: SARS-CoV-2; COVID-19; epidemiology; serological assay; cross-sectional study; higher 
education institutions; universities; undergraduates 
 
1. Introduction 
The devastating effect of COVID-19 has affected the public and private spheres, mod-
ifying our lifestyle and changing our relationship with our day-to-day environment. It has 
been already recognized that we are currently facing a new unprecedented pandemic with 
still unknown psycho-pathobiological aspects. 
In Europe, Spain occupies a significant place among the countries that suffered the 
devastating effects of the disease, as it was one of the first countries affected after Italy 
[1,2]. This led to the declaration of a lockdown by the government on 14 March 2020, con-
fining the population to their homes with strict measures to limit mobility. This situation, 
which lasted until 20 June of the same year, resulted in the closure of educational 
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institutions, which did not resume their activity until after the summer, during the first 
weeks of September. 
Due to the initial absence of an effective treatment or vaccine and of good diagnostic 
tools, this pandemic affected, and continues to affect, all areas of our society (including 
health, the economy, and education). Thus, proper patient management and limiting the 
spread of the virus is especially important [3]. Significant short, medium, and perhaps 
long-term consequences and disruptions from the pandemic appear to be inevitable, and 
these may become increasingly severe [4]. 
The World Bank estimated that, in April of 2020, universities and other tertiary edu-
cational institutions were closed in 175 countries and communities, and more than 220 
million post-secondary education students had their studies ended or significantly dis-
rupted due to COVID-19 [5]. Spain was one of the countries with the strictest conditions 
during the pandemic: leaving home was only allowed for essential needs [6], all universi-
ties were physically closed, and classes continued online with support from the Spanish 
government [7]. 
In recent months, the need to implement strategies to mitigate COVID-19 cases on 
university campuses for their safe reopening were addressed [8–11] in order to track pos-
sible outbreaks [12]. Faced with a possible skepticism or fear of returning to class due to 
risk perception [13], studies were carried out to simulate strategic models [14–17]. These 
studies showed that randomized testing, contact-tracing, and quarantining were im-
portant components of the strategy for containing campus outbreaks [13], as opposed to 
symptom-based screening [15,16], and also showed that these should be individualized 
according to each university [17].The feasibility of self-administered tests was verified 
[18], and the students' knowledge and behaviors regarding COVID-19 [19] or the preva-
lence of symptoms were explored [20], especially in health sciences or medicine depart-
ments [21–23]. Reopening campuses and preventing outbreaks requires careful delibera-
tion and the use of all scientific tools and advances available to develop plans and proto-
cols that are appropriate to their jurisdiction [24]. 
In our universities, the main concern was what training and education would be like 
from now on in a pandemic context. Is it possible to continue with traditional classes? This 
question was even more important in the health-related professions, where the students 
must practice using physical contact. Therefore, controversy was guaranteed, as the sero-
prevalence of this population was not well known. 
On the other hand, higher education institutions are uniquely placed to lead a coor-
dinated scientific and educational movement to shape a future that supports both people 
and the planet [11,25] through education, research, and advocacy [26]. 
Seroprevalence has been extensively explored in patients tested by RT-PCR [27,28], 
but few studies have assessed seroprevalence in asymptomatic individuals. In Spain, Pol-
lán et al. [29] carried out a large national and population-based sero-epidemiological 
study on the general population during the first wave of the pandemic (from April to May 
2020), and found that most of the population appeared to have remained unexposed to 
SARS-CoV-2, even in areas with widespread virus circulation [30]. Other epidemiological 
data published were not disaggregated by age groups, sex, social group, autochthonous, 
imported, etc. Likewise, there was an insufficient number of detection tests carried out 
(PCR, ELISA, or rapid tests) [30,31]. 
At the time of our study, a rapid diagnostic test for COVID-19 with a strong scientific 
support was not available. Many of these were under development, and their features 
were being evaluated or had problems [32–34]. However, detecting antibodies against 
SARS-CoV-2 (IgG, IgM, and IgA) plays a complementary role in providing epidemiolog-
ical information [35]. 
The Center of Disease Control and Prevention (CDC) recommended testing to diag-
nose COVID-19 as one key components of a comprehensive strategy, which should be 
used in conjunction with the promotion of behaviors that reduce spread, thereby 
Int. J. Environ. Res. Public Health 2021, 18, 1908 3 of 16 
 
 
maintaining healthy environments, maintaining healthy operations, and preparing for 
when someone becomes sick [24]. 
In this context, the University of Alicante (UA) decided to develop adequate plans 
and protocols to protect the university community and control the spread of SARS-CoV-
2. 
The aim of this study was to explore aspects related to the pandemic disease in our 
university community before the reopening of the 2020–2021 academic year. The aspects 
of special interest were associated with epidemiological surveillance for adopting strate-
gies for a safe return to university. 
2. Materials and Methods 
2.1. Study Design 
A seroprevalence cross-sectional design, with SARS-CoV-2 virus detection through 
a rapid immunoassay test, was utilized for the epidemiological study. The sample was 
selected from a representative random sample stratified by students, administrative staff, 
and faculty, and per academic program. The study was carried out, with a single test, 
organized over 13 days (6 July to 22 July 2020) before the reopening of the Alicante Uni-
versity after the summer vacation, with the maintenance of a strict protocol of protection 
for students and collaborators, and measures of social distancing. Simultaneously, a cross-
sectional survey was carried out to determine how the university community had dealt 
with the pandemic crisis, which is explained below. 
2.2. Sample Size Calculation 
The UA sample frame was comprised of 28,304 members (25,635 students, 2286 pro-
fessors, and 1383 administrative staff). The sample size was determined with equal prob-
ability of being selected, and to ensure sufficient precision for evaluating the percentage 
of participants immunized, assuming 5% of participants would be immunized, as re-
ported by the National Sero-epidemiological Study of Spain [29]. We included 1500 indi-
viduals to allow this percentage to be estimated with a precision of at least 1.1%, assuming 
a 3% failure-rate. 
2.3. Participants 
Two ethics committees approved the study, the Ethics Committee for Research with 
Medicines of the Alicante Health Department-General Hospital, and the Ethics Commit-
tee of the University of Alicante. 
After the approval of the study and maintenance of the confidentiality of the data, 
the Statistics Department from the University of Alicante (Data Processing Center) pro-
vided us with the list of randomized subjects, which included names, emails and/or tele-
phone numbers. There were two additional randomized lists to replace participants’ ab-
sences. Randomized subjects were invited to participate in the study and visit the Univer-
sity of Alicante, Faculty of Health Sciences, to carry out the test. Participation was volun-
tary and without incentives. 
2.4. Selection Criteria 
The participants had to belong to the university community (students, faculty, or ad-
ministrative staff) of the University of Alicante at the time of the study, whether or not 
they had become sick from the disease, and they had to have been selected for the study 
and given their written informed consent. Participants who declared immunodeficiency, 
immunosuppression treatment, or cancer were excluded. 
2.5. Detection of SARS-CoV-2 Antibodies and Test Performance 
The Cellex®  qSARS-CoV-2 IgG/IgM Rapid Test (Cellex Inc., Durham, NC, USA) was 
used [36,37]. This is a lateral flow immunoassay intended for the qualitative detection and 
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differentiation of IgM and IgG antibodies against SARS-CoV-2 in serum, plasma, or whole 
blood specimens, producing results in 15–20 min. The manufacturer reports a sensitivity 
and specificity of 93.75% (95% CI: 88.06–97.26%), and 96.40% (95% CI: 92.26–97.78%), re-
spectively, using RT-PCR as the gold standard. The test was verified by the Microbiology 
Service of the Valencia General Hospital Consortium, which has accreditation according 
to the UNE-EN ISO 15189: 2013 standard, which verified the characteristics of the test: a 
sensitivity of 87.80%; 99.9% specificity and an efficiency of 89.58% [38]. Twenty-two nurs-
ing students were trained to perform the test, proceeding according to the specifications 
recommended by the manufacturer and the Food and Drug Administration [36,37]. 
The whole blood sample was obtained directly from a finger-prick. Members of the 
research team supervised the reading of the final results. Positive cases required the as-
sessment of at least two team members. All the controversial cases required a consensus 
of three members of the research team. For the antibody positivity report, we followed the 
manufacturer's instructions [36]. 
2.6. Contact Tracing Assessment 
A protocol was implemented in cases of a participant from the staff group (faculty 
and administrative) obtaining a positive test result in the study, including a thorough ep-
idemiological investigation and contact tracing of colleagues who worked in the same fa-
cilities for 60 days before the test. Contact tracing started four days before the date indi-
cated by the patient until the day the test was performed. For asymptomatic cases, the 
period of investigation was based on the date of the test. The contacts were invited to 
participate in the study. In the student group, positive cases were provided with infor-
mation about confinement measures by a physician trained in COVID-19, and were then 
referred to their general practitioner. 
2.7. Cross-Sectional Survey 
A questionnaire designed ad hoc for the study was provided to the participants. It 
was previously evaluated by team members who gave their recommendations, ultimately 
approving the latest version by consensus. A pilot test was performed with 20 students 
from different programs other than Health Sciences to assess its comprehension. Partici-
pants in the pilot study were not taken into account for this analysis. 
Google Forms was the online platform chosen for delivering the self-administered 
surveys. To maintain anonymity, the email addresses used were not collected. Partici-
pants accessed this with a bar-code provided by the person who performed the blood test. 
The study’s purpose was explained, and the informed consent was signed before the 
finger blood sample was taken. While waiting for the result, the participants completed 
the survey in 10–15 min. 
The questionnaire included items such as: 
Socio-demographic variables (sex, age, nationality, group, and place of origin). 
• Variables related to risk factors described for SARS-CoV-2 infection, such as chronic 
diseases, smoking, history of a previous infectious process in the last 12 months, use 
of drugs and previous vaccinations, as well as sun exposure and physical activity. 
• Variables related to symptoms described for SARS-CoV-2 infection, contact with pos-
sible positive cases, and diagnosis of SARS-CoV-2 infection [39]. 
• To obtain an idea of the actions needed to be carried out in the following academic 
year at the University of Alicante, they were also asked about their usual form of 
travel to access the university, the reasons why they have left home during the con-
finement, and their predisposition towards receiving the influenza and/or SARS-
CoV-2 vaccine in the autumn, as well as the individual protection measures taken. 
• Lastly, they were asked about the sources of information that they regularly used to 
inform themselves about the pandemic, and possible expectations or demands for 
information and materials from the University. 
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2.8. Statistical Analysis 
We estimated the seroprevalence as the proportion of participants who had a positive 
test result in the rapid test IgG band. Assuming that the test used was imperfect, the esti-
mate was adjusted using the formula described by Greenland (1996) [40]. The result was 
weighted with the variables ‘sex’ and ‘staff/student’. 
A descriptive statistical analysis was performed. The means and standard deviations 
were calculated. We used Student’s t-test to compare the means, and Chi-square tests and 
Fisher’s exact test (categorical variables) were performed to examine differences between 
groups in all the questionnaire items. To assess the association between the independent 
variables and the two populations, odds ratios (OR) and adjusted odds ratios (ORa) were 
performed using a logistic regression, and the 95% CI was calculated. 
All the data were analyzed with the statistics program SPSS Statistics for Windows 
v20 (SPSS v20, IBM Corp., Armonk, NY, USA). The level of accepted statistical significance 
was p < 0.05. 
2.9. Ethical Considerations 
All the subjects received an informed consent form via email at the time of the invi-
tation to participate in the study, to be read before the test. The study complied with the 
Ethical Principles for Human Research standards, and the study protocol (and the rest of 
the documents) were approved by two Ethics Committees. 
The study was carried out following the Declaration of Helsinki and the EU Regula-
tion 134 2016/679 on personal data handling. Participation was completely voluntary and 
all the participants were asked to provide their informed consent in writing and to sign 
this before the blood sample was taken and before obtaining the barcode. The participants 
were informed that all the information collected would be anonymous and treated as con-
fidential. The participants could not be identified from the collected material. 
3. Results 
3.1. Prevalence Study 
1479 subjects were studied from the randomized sample. We could not reach out to 
21 students from the seroprevalence study, and 7 of them refused to participate, because 
they lived far from the UA. Therefore, the response ratio was 0.99. 
Overall, the seroprevalence found for the university community of Alicante in the 
study period from 6 July to 22 July 2020, was 39/1479 (2.64%; 95% CI 1.8–3.4) through the 
use of the lateral flow immuno-assay test. The adjusted seroprevalence, according to the 
data from the Valencian study [38], was 2.89% (95% CI 2.1–3.7) (Table 1). 
Table 1. Seroprevalence of immunity against SARS-CoV-2 in the University community. 
Prevalence Study Prevalence 
95% CI 
LL (%) UL (%) 
Weighted Prevalence 2.64 1.84 3.43 
Adjusted prevalence (se: 87.80%; sp: 99.9%) * 2.89 2.06 3.73 
* Valencian study [38]; se = sensitivity; sp = specificity; LL = Lower Limit; UP = Upper Limit. 
3.2. Population Characteristics and Survey Response 
The cross-sectional study sample comprised of 1359 subjects, and the response rate 
for the survey was 0.92 (1359/1479). Among the participants who answered the question-
naire, 1021 (75.1%) were students, and 338 (24.9%) were faculty and staff members. Of 
these, 919 (67.6%) were women (male: female ratio = 0.47), and the mean age was 23.2 
years old (±6.4) in the student group, and 47.6 (±9.5) in the staff group. Only 1.6% (22/1359) 
were foreigners (Table 2). 
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Blood group A was predominant at 48.2% (509/1056), and 19.1% (260/1359) con-
firmed suffering from a chronic disease. Globally, the most reported chronic diseases were 
allergy/asthma (4.8%; 65/1359), cardiovascular (4.1%; 56/1359), and metabolic diseases 
(3.9%; 53/1359). Allergies were more frequent in the group of students (5%; 51/1021), while 
in the staff group, cardiovascular diseases were more frequent (10.4%; 35/338). None of 
the participants declared immunodeficiency, immunosuppression treatment, or cancer. 
There were no differences in smoking between both groups. Still, we found signifi-
cant differences in the mean number of cigarettes/day between the populations: 6 (±4.77) 
in the student group, and 10.2 (±7.28) in the staff sample (p = 0.001). 











Overall Test Result 
Positive 25 (2.4) 14 (4.1) 39 (2.9) 1.7 (0.9–3.4) NS 
Negative 996 (97.6) 324 (95.9) 1320 (97.1)   
Sex 
Female 733 (71.8) 186 (55.0) 919 (67.6) 0.5 (0.4–0.6) <0.001 
Male 288 (28.2) 152 (45) 440 (32.4)   
Nationality 
Spanish 1002 (98.1) 335 (99.1) 1337 (98.4) 0.5 (0.1–1.6) NS 
Other 19(1.9) 3(0.9) 22(1.6)   
Blood group (n = 1056) ** 
A 390 (48.7) 119 (46.7) 509 (48.2) Ref  
AB 28 (3.5) 10 (3.9) 38 (3.6) 0.9 (0.7–1.2) 0.524 
B 68 (8.5) 20 (7.8) 88 (8.3) 1.1 (0.5–2.3) 0.877 
O 315 (39.3) 106 (41.6) 421 (39.9) 0.9 (05–1.5) 0.628 
Smoking * 
Yes 118 (11.6) 46 (13.6) 164 (12.1) 1.2 (0.8–1.7) NS 
No 903 (88.4) 292 (86.4) 1195 (87.9)   
Chronic diseases 
Yes 153 (15.0) 107 (31.7) 260 (19.1) 2.6 (2–3.5) <0.001 
No 868 (85.0) 231 (68.3) 1099 (80.9)     
* Smoking (number of cigarettes/day). Age (years). NS (Not Significant).** Blood group declared 
by participants. CI = confidence interval. Ref = reference. 
Table 3 shows the distribution of anti-SARS CoV-2 results in students and faculty 
and administrative staff. The high prevalence in female students should be noted, as only 
16% (4/25) of the positive tests results were from male students. This could be associated 
with the male/female ratio of the students. There were four participants who reported a 
previous positive PCR SARS-CoV-2 test; three of them had positive antibody tests. Only 
28% (7/25) of the positive cases reported some prior illness with respiratory symptoms 
during the 14 days before the study. 
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Table 3. Prevalence of anti-SARS CoV-2 in students and faculty and administrative staff. 





Total OR (95% CI) p 
Students (N = 1021)  996 25 1021   
Age (years), mean (SD) 23.2 (6.4) 22.9 (8.3)   NS 
Gender, Female 712 (71.5) 21 (84) 733 (71.8) 2.1 (0.7–6.2) NS 
History PCR SARS-CoV-2 (+) 1 (1.0) 2 (8) 3 (2.9) 0.02 (0.3) 0.02 
Smoking 116 (11.6) 2 (8) 118 (11.6) 0.7 (0.2–2.8) NS 
Chronic diseases 150 (15.1) 3 (12) 153 (15) 0.8 (0.2–2.6)  
Self-reported symptoms ▪ 224 (22.5) 7 (28.0) 219 (21.5) 1.3 (0.6–3.2) NS 
Reported contact with 1 con-
firmed (PCR) COVID-19 
14 (1.4) 3 (12.0) 17 (1.7) 9.6 (2.6–35.6) 0.007 
Infection disease 12 month pre-
vious 
136 (13.7) 5 (20.0) 141 (13.8) 1.6 (0.5–4.2) NS 
Vaccination 12 months previous 158 (15.9) 6 (24.0) 164 (16.1) 1.7 (0.6–4.2) NS 
Staff (N = 338) 324 14 338   
Age (years), mean (SD)  47.5 (9.4) 51.9 (11.8)   NS 
Gender, Female  180 (55.6) 6 (42.7) 186 (55.0) 0.6 (0.2–1.8) NS 
History PCR SARS-CoV-2 (+)  0 (0) 1 (7.1) 7 (2.0)  0.001 
Smoking 44 (13.6) 2 (14.3) 46 (13.6) 1.1 (0.2–4.9) NS 
Chronic diseases 99 (69.2) 8 (80.0) 107 (69.9) 3 (1.02–9) 0.036 
Self-reported symptoms 48 (14.8) 2 (14.3) 39 (11.5) 0.9 (0.2–4.5) 0.037 
Reported contact with 1 con-
firmed (PCR) COVID-19 
2 (0.6) 1 (7.1) 3 (0.9) 12.3 (1.1–14) NS 
Infection disease 12 month pre-
vious 
27 (8.3) 3 (21.4) 30 (8.9) 3 (0.7–11.4) NS 
Vaccination 12 months previous 51 (15.8) 1 (7.1) 52 (15.4) 0.4 (.05–3.2)  NS 
▪ pauci-symptomatic (1–2 symptoms without anosmia or ageusia), and symptomatic (anosmia or 
ageusia, or at least three symptoms among fever; chills; severe tiredness; sore throat; cough; short-
ness of breath; headache; or nausea, vomiting, or diarrhea) during the 14 days before study. 
Table 4 shows the characteristics of the population related to the symptoms described 
for SARS-CoV-2 infection. Only 18.9% (258/1359) reported symptoms in the two–three 
weeks before the date of the serological study, and 14 of them reported ageusia and/or 
anosmia (5.4%; 14/258).  
During the confinement period (between March and April), most participants cohab-
ited with another three to five people (55.2%; 750/1301). In addition, 1.5% (20/1359) af-
firmed to living at home with a positive case of SARS-CoV-2, and 4.9% (66/1359) remained 
strictly confined at home due to medical recommendations. 
Additionally, 3.1% (42/1359) had taken a PCR test for SARS-CoV-2, and four were 
positive. Similarly, 2.5% (35/1359) had taken a serological test, and only one resulted as 
positive. 
In regard to suffering infections in the 12 months prior to the test, 12.6% (171/1359) 
had had some type of infection. The most frequent, 7.7% (105/1359), were related to res-
piratory infections, and there was a statistically significant difference between the groups 
of students and staff. 
Lastly, 15.8% (215/1359) had received a vaccine in the 12 months before the survey. 
The most frequent vaccine was against influenza (9.1%; 123/1359), followed by the menin-
gococcal (2.1%; 29/1359) vaccine. Allergy vaccines had been received by 1.5%. 
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Table 4. Characteristics related to SARS-CoV-2 infection symptoms (n = 1359). 







OR (95% CI) p 
Self-reported symptoms † 
Asymptomatic 802 (78.6) 299 (88.5) 1101 (81) Ref  
Pauci-symptomatic 204 (20) 36 (10.7) 240 (17.7) 0.5 (0.3–0.7) <0.001 
Symptomatic ≤14 days 
before study 
15 (1.5) 3 (0.9) 18 (1.3) 0.5 (0.1–1.9) 0.328 
Household size, residents (n = 1301) 
One 133 (13.4) 92 (30.2) 225 (17.3) Ref   
Two 214 (21.5) 83 (27.2) 297 (22.8) 0.7 (0.4–0.8) 0.002 
Three to five 622 (62.4) 128 (42) 750 (57.6) 0.3 (0.2–0.4) <0.001 
Six or more 27 (2.7) 2 (0.7) 29 (2.2) 0.1 (0.03–0.5) 0.003 
Household member with confirmed case  
No contact 1004 (98.3) 335 (99.1) 1339 (98.5) 
0.53 (0.15–1.82) NS 
Household member 17 (1.7) 3 (0.9) 20 (1.5) 
Household member with symptomatic person 
No contact 828 (81.1) 278 (82.2) 1106 (81.4) 
0.93 (0.67–1.28) NS 
Household member 193 (18.9) 60 (17.8) 253 (18.6) 
Contact with confirmed case last month 
Contact 59 (5.8) 15 (4.5) 74 (5.5) 
0.76 (0.43–1.36) NS 
No contact 958 (94.2) 320 (95.5) 1278 (94.5) 
Confined during the last month 
Confined 55 (5.4) 11 (3.3) 66 (4.9) 
0.59 (0.31–1.14) NS 
No 966 (94.6) 327 (96.7) 1293 (95.1) 
Self-reported PCR status 
Never done 991 (97.1) 326 (96.4) 1317 (96.9) Ref  
Negative 27 (2.6) 11 (3.3) 38 (2.8) 0.8 (0.62–2.4) NS 
Positive (>14 days before 
study visit) 
3 (0.3) 1 (0.3) 4 (0.3) 0.8 (0.3–1.6)  
Self-reported serologic status 
Never done 992 (96.8) 332 (97.9) 1324 (97.1) Ref  
Negative 32 (3.1) 7 (2.1) 34 (2.9) 0 NS 
Positive (>14 days before 
study visit) 
1 (0.1) 0(0) 1 (0.1) 1.5 (0.6–3.5)  
Infection disease 12 month prior 
No 880 (86.2) 308 (91.1) 1188 (87.4) Ref   
Respiratory diseases 81 (7.9) 24 (7.1) 105 (7.7) 0.8 (0.5–1.4) 0.491 
No respiratory diseases 60 (5.9) 6 (1.8) 66 (4.9) 0.3 (0.1–0.7) 0.004 
Vaccination 12 months prior 
No 857 (83.9) 287 (84.9) 1144 (84.2) 
0.93 (0.66–1.31) NS 
Yes 164 (16.1) 51 (15.1) 215 (15.8) 
† Asymptomatic (no symptoms), pauci-symptomatic (1–2 symptoms without anosmia or ageusia), 
and symptomatic (anosmia or ageusia, or at least three symptoms among fever; chills; severe 
tiredness; sore throat; cough; shortness of breath; headache; or nausea, vomiting, or diarrhea). Ref 
= reference. 
Some variables related to attitudes towards SARS-CoV-2 infection were explored, 
which are shown in Table 5. Most of the participants declared using hydrogel (97.6%; 
1324/1357) and hand washing (96.6%; 1309/1355) as the main protection measure; a mask 
was used by 94% (1277/1358), and physical distancing by 88.5% (1198/1353). 
Only 2.7% (37/1359) affirmed not having any reasons for leaving their home during 
the confinement, mainly students. The majority (61%; 829/1359) recognized at least two 
reasons for leaving home, such as to shop (72%; 978/1359), or go for a walk (63.6% 
864/1359), with no differences between the two groups. 
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We found that 70.5% (958/1359) of the subjects did some type of physical exercise, 
with an average of 5.8 ± 7.8 h/week, without statistically significant differences between 
both groups. The primary activity was walking 18.7% (214/1145), and 33% (429/1272) per-
formed indoor activities (such as gymnastics, cardiovascular, or bodybuilding exercises). 
An average of 2.5 ± 2.1 hours of sun exposure was reported, with a statistically significant 
difference between both groups (2.7 ± 1.9 students and 1.9 ± 2.6 staff p = 0.005). 
We also found that if a COVID-19 vaccine were available, 91% (1210/1329) would be 
willing to use it, while only 31% (407/1312) would obtain a flu vaccine in the fall. 








OR (95% CI) p 
Individual protection measures 
Wearing a face mask (n = 1358) 
No 64 (6.3) 17 (5) 81 (6) 
1.3 (0.7–2.2) NS 
Yes 956 (93.7) 321 (95) 1277 (94) 
Wash hands regularly (n = 1355) 
No 43 (4.2) 3 (0.9) 46 (3.4) 
4.9 (1.5–15.9) 0.003 
Yes 975 (95.8) 334 (99.1) 1309 (96.6) 
Use hydroalcoholic gel (n = 1357) 
No 23 (2.3) 10 (3) 33 (2.4) 
0.8 (0.4–1.6) NS 
Yes 997 (97.7) 327 (97) 1324 (97.6) 
Follow social distancing (n = 1353) 
No 150 (14.7) 5 (1.5) 155 (11.5) 
11.5 (4.7–28.2) 
 
Yes 867 (85.3) 331 (98.5) 1198 (88.5)  
Reasons for departure * (n = 1359) 
Remain confined 31 (3) 6 (1.8) 37 (2.7) Ref  
2 reasons for leaving 622 (60.9) 207 (61.2) 829 (61) 1.7 (0.7–4.2) 0.232 
>3 reasons for leaving 368 (36) 125 (37) 493 (36.3) 1.8 (0.7–4.3) 0.219 
Perform physical exercise (n = 1357) 
No 326 (31.9) 75 (22.2) 401 (29.5) 
1.6 (1.2–2.2) 0.001 
Yes 695 (68.1) 263 (77.8) 958 (70.5) 
Would get COVID-19 vaccine (n = 1329) 
No 90 (8.9) 29 (9) 119 (9) 
1 (0.6–1.5) NS 
Yes 916 (91.1) 294 (91) 1210 (91) 
Is going to get flu vaccines (n = 1312) 
No 701 (71.4) 204 (61.8) 905 (69) 
0.6 (0.5–0.8) 0.001 
Yes 281 (28.6) 126 (38.2) 407 (31) 
Ref = reference. 
As for how the participants traveled to the University campus during the academic 
period, we found that 91% (1235/1359) generally arrived with a motorized vehicle, and 
only 9.1% (124/1359) attested arriving on foot or by bicycle (Table 6). A private/individual 
car (66.6%; 905/1359) was the most common vehicle used by both groups, followed by the 
bus (30.5%; 415/1359). 
Both groups used the internet and television as the media of choice for obtaining 
information about the pandemic and the SARS-Cov-2 infection; the primary demand on 
the University was accessible information on the university’s website and training 
courses. Lastly, the majority would repeat (87.9%; 1195/1359) the rapid test in a new study. 
Table 6. Mobility, sources of information and expectations. 
Variable Students Staff Total   
 N (%) N (%) N (%) OR (95% CI) p 
Ways to access to the university 
On foot/by bicycle 101 (9.9) 23 (6.8) 124 (9.1) 1.5 (0.9–2.4) NS 
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Motorized vehicle 920 (90.1) 315 (93.2) 1235 (90.9)   
Use of means of transport 
Private car 623 (61) 282 (83.4) 905 (66.6) 3.2 (2.4–4.4) <0.001 
Bus 388 (38) 27 (8) 415 (30.5) 0.1 (0.1–0.2) <0.001 
On foot 171 (16.7) 30 (8.9) 201 (14.8) 0.5 (0.3–0.7) <0.001 
Shared vehicle 168 (16.5) 9 (2.7) 177 (13) 0.1 (0.1–0.3) <0.001 
Motorcycle 20 (2) 17 (5) 37 (2.7) 2.7 (1.4–5.1) 0.003 
Bicycle 37 (3.6) 20 (5.9) 57 (4.2) 1.7 (1–2.9) NS 
Information media 
Internet 807 (79) 199 (58.9) 1006 (74) 0.4 (0.3–0.5) <0.001 
Television 718 (70.3) 235 (69.5) 953 (70.1) 1 (0.7–1.3) NS 
Social networks 561 (54.9) 75 (22.2) 636 (46.8) 0.2 (0.2–0.3) <0.001 
Digital press 413 (40.5) 182 (53.8) 595 (43.8) 1.7 (1.3–2.2) <0.001 
Official website 489 (47.9) 105 (31.1) 594 (43.7) 0.5 (0.4–0.6) <0.001 
Radio  153 (15) 98 (29) 251 (18.5) 2.3 (1.7–3.1) <0.001 
Non-official website 55 (5.4) 8 (2.4) 63 (4.6) 0.4 (0.2–0.9) 0.02 
Expectations towards the University regarding COVID-19 
None 17 (1.7) 5 (1.5) 22 (1.6) Ref  
Provide individual training 
teams 
180 (17.6) 177 (52.4) 357 (26.3) 3.3 (1.2–9.3) 0.020 
Information accessible from 
a website 
500 (49) 113 (33.4) 613 (45.1) 0.8 (0.3–2.1) 0.612 
Specific training on the pan-
demic 
324 (31.7) 43 (12.7) 367 (27) 0.5 (0.2–1.3) 0.130 
Would repeat the test 
No 8 (0.8) 0 (0) 8 (0.6)   
Yes 880 (86.2) 315 (93.2) 1195 (87.9) Ref  
Maybe 133 (13) 23 (6.8) 156 (11.5) 0.5 (0.3–0.8) 0.002 
Ref = reference. 
3.3. Contact Tracing Assessment 
We listed 103 persons from the university environment in the contact-tracing study 
of 14 positive cases among the randomized staff members. We reached out to 94 individ-
uals and detected two secondary cases with an infection risk of 2.1% (95% CI, 0.5%–1.2%). 
4. Discussion 
In our study, the prevalence of IgG antibodies against SARS-CoV-2 from the 6th to 
the 22nd of July 2020, in a randomized sample of students and faculty and administrative 
staff from the University of Alicante, was 2.64%. These data are in agreement with the 
2.4% observed in our region in the first wave of the ENE-COVID study [29], a population-
based study. Our findings assessed the situation during the first wave, as the pandemic 
started to improve in early July. Afterwards, the second wave would begin, which has not 
yet remitted. 
Tilley et.al. [41] in the USA (Los Angeles), and Tsitsilonis et.al. [42] in Greece (Ath-
ens), obtained similar results. The seroprevalences of the university community and in the 
general population were very similar. 
Other seroprevalence studies have been conducted, and the efficacy of different test-
ing strategies in higher education institutions is still being evaluated. In their study, 
Blaisdell et.al. [43] suggested that a two-phased universal testing strategy may be effective 
in minimizing transmission, and the experiences of the University of Texas and North 
Carolina University highlights the potential for rapid transmission on campus [12,44,45]. 
Gillam et.al. [18] proposed that repeated self-testing for COVID-19 using PCR is feasible 
and acceptable for a university population. 
To our knowledge, this study is the first in Spain with an academic population. We 
have to add that there was a good acceptance rate to participate among those invited. 
Int. J. Environ. Res. Public Health 2021, 18, 1908 11 of 16 
 
 
We found no differences in seroprevalence between students and faculty and staff, 
although not everyone who is infected with COVID-19 will develop an immune response 
[44]. 
Other studies have shown that universal testing may have a significant impact on the 
control of the virus, depending on the ability of the location to implement other control 
measures [44], but universal testing and testing symptomatic people are not well studied 
as testing programs for COVID-19 at a university campus [18], and the type of test that 
would be the most useful in the university context considered is still unknown. 
There is still no consensus on the forms and types of approach that could be used to 
evaluate students for COVID-19 when returning to the university campus [16]. In general, 
different institutions have different proposals regarding the initial tests 
[3,9,19,24,33,46,47]. In Spain there is no consensus among the different regions, and at the 
central government level only very general recommendations have been made. Even now, 
scientific publications are only just starting to appear with discussions, considerations, 
and modeling of possible preventive strategies and their cost-effectiveness when it comes 
to reopening the university [8,14,15,48]. 
In our study, we found statistically significant differences between students and the 
university staff in almost all the factors explored, but it is remarkable that smoking was 
similar in both groups, so that both have the same risks associated with smoking. It was 
confirmed that the asymptomatic and pauci-symptomatic states, even if self-reported, 
were very frequent (they represented nearly 80% of the cases). Therefore, it is important 
to identify this quickly to prevent infection. While most of the students spent their lock-
down in the family home with three to five family members, only 1.5% of them claimed 
to live with a SARS-CoV-2 positive case. These results are possible given the prevalence 
shown by the Ministry of Health at that time [29]. 
From the sample, 3% reported having undergone a PCR test for SARS-CoV-2, and of 
these four were positive. Additionally, 2.5% had done a serological test, and only one had 
received a positive result. The problems with the SARS-CoV-2 diagnostic tests (both PCR 
and antibodies test) are mainly the direct and indirect costs, and the variability in their 
sensitivity and specificity. This has been demonstrated and assessed in different studies, 
and reviewed in a systematic metanalysis [33]. 
Among all the positive cases, only 23% (9/39) had symptoms. This finding is im-
portant in a university campus; if large numbers of the population are asymptomatic or 
have mildly symptomatic infections, seroprevalence estimation studies may underrepre-
sent the prior incidence of the disease. 
In addition, important aspects of this infection are not yet known, such as the dura-
tion of immunity or the number of antibodies that are necessary to be protected, and 
whether or not reinfection and cross-reactivity with human endemic coronavirus are pos-
sible [27]. 
Approximately 95% of the participants declared following proper prevention meth-
ods against the spread of the virus, such as washing their hands regularly, wearing a face 
mask, following social distancing measures, and using hydroalcoholic gel. This result was 
higher than other studies conducted at about the time of the present study [19,21,23]. 
Most students and staff (91%) stated that they would receive a COVID-19 vaccine 
immediately if available; Chesser [19] found lower data in a university population (68%), 
but this contrasts with the 31% of all participants who would get the flu vaccine, and this 
could be the effect of a greater perception of severity and uncertainty produced by 
COVID-19.  
The most accessed sources for current COVID-19 information were the internet (79%) 
and television (70.3%), among students, in agreement with previous studies [19,23]. The 
significant differences found regarding the use of information sources between students 
and staff groups were remarkable; the students preferred social media, and the faculty 
and administrative staff preferred the digital press as they type of media used to inform 
themselves about the pandemic topics. This information could help health educators to 
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develop communication strategies to improve their reach and the knowledge of the pop-
ulation [19]. In addition, students' demands showed the need for more information on the 
University's website, more training courses, and individual training teams. This is an in-
dication of the interest in our community in being up-to-date on the subject of COVID 19, 
as 87.9% indicated that they would be willing to repeat the test, which indicates the ma-
jority acceptance of this initiative and their favorable predisposition towards it. 
Considering that clear leadership was necessary to confront this emergency [11], a 
multidisciplinary working group was created and coordinated by a medical epidemiolo-
gist appointed by the University Rector on 1 May 2020. Each of the faculties provided a 
person who would be responsible for COVID-19 related matters, who joined the working 
group. A single institutional email on COVID-19 and a contact telephone number were 
established [11]. 
Following the guidelines recommended by the health and academic authorities, the 
University of Alicante (UA) prepared, on 10 July 2020, a Risk Prevention Guidelines 
against COVID-19, with all the necessary prevention measures to be implemented in Sep-
tember of the 2020/2021 academic year, with guarantees of a safe reopening according to 
the epidemiological situation. 
Individual preventive measures (mandatory use of face masks, physical distance, 
hand hygiene), and collective measures (natural ventilation, disinfection of classrooms, 
signage, isolation rooms) were encouraged; short training courses on COVID-19 epidemi-
ology and prevention were held, aimed at different groups in the community; people with 
vulnerabilities were specified to telework, and a bimodal teaching method was chosen. 
A Webpage on Coronavirus (Figure 1) was also created with its own and external 
content on training and dissemination. A COVID-19 Unit formed by health workers was 
created for the epidemiological surveillance and monitoring of cases and contacts. This 
unit, from 3 September to 18 December, tracked a total of 731 individuals with 200 positive 
PCR cases (152 students, 30 professors, 18 staff), and 531 close or suspicious contacts (276, 
83, 172). In both cases, the detected persons were advised to stay in isolation (positive) or 
quarantine (close contact) for 10 days. They were followed-up by telephone to check their 
health status and to verify the absence of symptoms and positive tests. Random screening 
was and is being carried out by testing a random sample of the university population [8]. 
The antibody test was repeated in 37 of the 39 cases with a positive IgG result in July, 
which confirmed the same results, so these individuals had maintained their immunity 
throughout these past six months. 
We could point out some limitations of our study. It was carried out in a specific 
population, thus the extrapolation of the results cannot be applied directly to the general 
population. However, the study serves to obtain preliminary information for future stud-
ies that are specifically designed, and we consider it representative of the university com-
munity. Hence, the findings were useful for decision-making during the reopening of the 
campus phase. Another limitation is inherent to the test. The test used to detect antibodies 
against SARS-CoV-2 in vitro is a qualitative test that does not determine the quantitative 
value or the rate of the increased levels of antibodies to SARS-CoV-2. This limits the scope 
of the estimation of the immunological status of the population, as a positive result with 
an insufficient amount of antibodies to protect against re-infection could be the case. 




Figure 1. Coronavirus website of the University of Alicante: www.coronavirus.ua.es. 
5. Conclusions 
Different strategies based on testing must be implemented as part of a broader 
COVID-19 prevention plan that must be developed by higher education institutions, 
which can be adapted according to increases in knowledge, and incorporating new pre-
ventive measures such as vaccination. 
Vaccines against COVID-19 are a reality; in December, vaccination was set to begin 
in several countries. The 27 member states of the European Union begun vaccinating on 
27 December 2020, a symbolic date to reaffirm unity of action, and coinciding with the 
declaration of the first cases of the disease a year prior. However, this encouraging news 
does not allow us to lower our guard, as the number of cases and deaths from COVID-19 
continues to rise. 
Likewise, the higher education institutions’ population is not part of the most vul-
nerable groups and is not among those who will have priority access to vaccination. 
Therefore, it will be necessary to continue to maintain active epidemiological surveillance 
and follow-up of cases and contacts, carry out screening strategies, decide a flexible teach-
ing model for the coming months, persist in training in individual and collective preven-
tive measures, and take the opportunity to explain and describe the advantages of vac-
cination to the university community, eliminating any doubts about its efficacy and safety. 
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